On Tuesday 14 July 2015, the BBC returns to Great Ormond Street Hospital (GOSH) for a third documentary series. Follow our young patients and their specialists as they undergo treatment for their rare diseases, respiratory disorders and neurological conditions.
Injecting cells from pregnant women could have a life-changing effect on the millions who are living with osteoporosis and brittle bone disease according to researchers at the UCL GOS Institute of Child Health, the research partner of Great Ormond Street Hospital and The UCL Institute for Women’s Health. These cells could also be useful for strengthening the fragile bones of astronauts during their stay for long periods in space.
Researchers from the UCL Great Ormond Street Institute of Child Health have discovered a new gene change that identifies a type of the movement disorder, muscle dystonia. This new discovery will allow doctors to more easily identify patients who can benefit from treatment so effective that it can restore the ability to walk.
Research led by Diagnostics and Imaging Theme lead, Professor Neil Sebire aimed to investigate which aspects of post-mortem examinations in stillbirths are most effective at providing a cause of death.
GOSH BRC-funded, Senior research associate, Dr Wendy Heywood has been awarded £98,000 from the UCL Confidence in Concept fund to develop newly discovered biomarkers for disease stratification of mucopolysaccharidosis (MPS) into a clinical assay for validation.
A Non-Invasive Prenatal Test (NIPT) evaluated by a team led by BRC-supported Professor Lyn Chitty is to be introduced into the NHS for the screening of Down’s syndrome, Edwards’ syndrome and Patau’s syndrome.
Research led by BRC Deputy Director Professor Bobby Gaspar and supported by the BRC-funded GOSgene facility, has found that a mutation in the linker for activation of T-cells (LAT) gene leads to a specific form of severe combined immunodeficiency (SCID).
The United States Food and Drug Administration (FDA) granted accelerated approval for a new medication to treat Duchenne muscular dystrophy (DMD). The drug, Eteplirsen, was developed by a UK consortium led by Novel Therapies Theme lead, Professor Francesco Muntoni.
BRC-supported Dr Philippa Mills, Professor Peter Clayton and Professor Paul Gissen have led an investigation into the effectiveness of a gene panel, targeting 614 genes, in establishing a diagnosis for patients presenting with a wide array of neurometabolic phenotypes.
GOSH Arts are recruiting freelance artists and creative practitioners from a range of backgrounds including visual artists, performers, dancers, musicians, story tellers, writers and other creative fields to undertake the role of freelance artist at GOSH.
The multi-disciplinary Feeding Disorders Team at Great Ormond Street Hospital (GOSH) is pleased to offer a series of six half-day clinical workshops. The sessions can be attended on a single session basis; alternatively, participants can sign up for all six.